I-Mab (NASDAQ:ARQT) posted its earnings results on Tuesday. The company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.10), Fidelity Earnings reports.

ARQT stock opened at $26.13 on Friday. I-Mab has a 12-month low of $17.10 and a 12-month high of $40.88. The business has a 50-day moving average price of $28.64.

Separately, Zacks Investment Research upgraded I-Mab from a “sell” rating to a “hold” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. I-Mab currently has an average rating of “Buy” and a consensus target price of $41.00.

In related news, Director Howard G. Welgus sold 2,800 shares of I-Mab stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $25.63, for a total value of $71,764.00. Following the sale, the director now directly owns 162,725 shares in the company, valued at approximately $4,170,641.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

About I-Mab

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Featured Story: How does equity income fit into an investing strategy?

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.